Get the Stockscreener App
1.1812
4.03%
-0.0588
Allogene Therapeutics Inc stock is traded at $1.1812, with a volume of 701.25K.
It is down -4.03% in the last 24 hours and down -10.53% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.24
Open:
$1.25
24h Volume:
701.25K
Relative Volume:
0.19
Market Cap:
$262.93M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.5572
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-3.25%
1M Performance:
-10.53%
6M Performance:
-30.00%
1Y Performance:
-56.25%
1-Day Range:
$1.18
$1.26
1-Week Range:
$1.18
$1.31
52-Week Range:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.185 | 275.13M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.04 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.97 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.73 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.50 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
179.48 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Allogene to present pivotal trial design for lymphoma therapy at ASH - Investing.com
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting - The Manila Times
Why Allogene Therapeutics Inc. stock remains on watchlistsJuly 2025 Short Interest & AI Based Buy and Sell Signals - newser.com
Analyzing Allogene Therapeutics Inc. with multi timeframe chartsJuly 2025 Trends & Community Verified Trade Signals - newser.com
How sentiment analysis helps forecast Allogene Therapeutics Inc.Weekly Trade Review & Daily Profit Maximizing Tips - newser.com
Will breakout in Allogene Therapeutics Inc. lead to full recoveryWeekly Market Report & High Accuracy Investment Signals - newser.com
Using AI based signals to follow Allogene Therapeutics Inc.Weekly Gains Report & Smart Swing Trading Techniques - newser.com
Published on: 2025-11-02 23:31:58 - newser.com
Chart based analysis of Allogene Therapeutics Inc. trends2025 Top Decliners & Daily Profit Focused Screening - newser.com
Price action breakdown for Allogene Therapeutics Inc.Earnings Overview Report & AI Powered Trade Plan Recommendations - newser.com
Risk adjusted return profile for Allogene Therapeutics Inc. analyzedPortfolio Growth Summary & AI Driven Stock Reports - newser.com
Applying Elliott Wave Theory to Allogene Therapeutics Inc.Quarterly Portfolio Report & Consistent Profit Trading Strategies - newser.com
Published on: 2025-11-02 02:58:33 - newser.com
What candlestick patterns are forming on Allogene Therapeutics Inc.Chart Signals & Community Trade Idea Sharing Platform - newser.com
Detecting support and resistance levels for Allogene Therapeutics Inc.July 2025 WrapUp & AI Forecast for Swing Trade Picks - newser.com
Allogene Therapeutics (ALLO) to Release Quarterly Earnings on Thursday - MarketBeat
Will Allogene Therapeutics Inc. stock remain a Wall Street favoriteDollar Strength & High Return Trade Opportunity Guides - newser.com
Will Allogene Therapeutics Inc. stock deliver better than expected guidanceJuly 2025 Pullbacks & Pattern Based Trade Signal System - newser.com
Allogene Therapeutics (NASDAQ: ALLO) sets Q3 2025 results; webcast at 2 p.m. PT - Stock Titan
Will Allogene Therapeutics Inc. stock beat EPS estimatesEarnings Risk Report & Free Growth Oriented Trading Recommendations - Fundação Cultural do Pará
Using portfolio simulators with Allogene Therapeutics Inc. includedQuarterly Earnings Report & Safe Entry Point Alerts - newser.com
Allogene Therapeutics targets lupus with RESOLUTION trial launch - Traders Union
Will Allogene Therapeutics Inc. stock deliver strong dividend growthGap Down & Short-Term Trading Alerts - Fundação Cultural do Pará
Pharma News: Will Allogene Therapeutics Inc. stock deliver better than expected guidance2025 Winners & Losers & AI Powered Buy and Sell Recommendations - Fundação Cultural do Pará
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.03%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):